基因多态性对地高辛代谢影响的研究进展

Advances in Gene Polymorphism Studies on Digoxin Metabolism

地高辛作为临床上治疗充血性心力衰竭的经典药物,因其作用持久、价格低廉且不容易产生耐药现象,广泛地用于各种急慢性心功能不全、室上性心动过速、心房扑动及心房颤动等疾病的治疗。因地高辛的治疗浓度接近中毒浓度,如何在其狭窄的治疗窗内提高疗效,保证安全有效地应用地高辛,一直是临床亟待解决的问题。近年来,对地高辛的药物基因组学研究发现,某些基因位点的多态性可影响地高辛的药物代谢及作用,从而部分解释了患者对地高辛有效剂量的个体差异。本文就近年来涉及的地高辛药物基因组学研究进行综述,以期为地高辛的个体化用药提供参考。

As a classic drug for the treatment of congestive heart failure, digoxin is widely used invarious of diseases for its persistent efficacy, low price, anti-drug resistance, such as acute or chronic car-diac function insufficiency, supraventricular tachycardia, atrial flutter, atrial fibrillation, etc. As everyoneknows, therapeutic concentrations and toxic concentration of digoxin are close, how to improve the outcomeunder its narrow therapeutic window, to ensure safe and effective use of digoxin, has been a thorny clinicalproblems to be solved. In recent years, studies on pharmacogenomics of digoxin, have found that some ge-netic locus polymorphism can affect the metabolism and function of digoxin which can partly explain indi-vidual differences on digoxin pharmacodynamics. This paper reviewed digoxin pharmacogenomics studiesfrom the perspective of drug metabolism in recent years, so as to provide reference for digoxin individual-ized medication.